Phase II study of MGI-114 (NSC# 683863) administered intravenously for five days every 28 days to patients with metastatic colorectal cancer
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2018
At a glance
- Drugs Irofulven (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 28 Sep 2010 Status changed from Active,not recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Sep 2005 New trial record.